CGM: Is “More” always better? Abbott’s Libres. More Data – part 2
In the first part of these two sections dedicated to Libre’s minute by minute data, we looked at how the data presented and what that […]
Blog Posts
CGM: Is “More” always better? Abbott’s Libres. More Data – part 1
Abbot – More data In the first part of this series, we looked at Dexcom, it’s claims of greater accuracy, and what benefit that provided. […]
CGM: Is “More” always better? Dexcom’s G7. More Accurate
As we discussed in the first article in this series, there’s a lot of marketing about having More with your CGM, whether that’s accuracy or […]
CGM: Is “More” always better?
Over the past few years we’ve seen a number of the larger CGM manufacturers allowing us to infer that their newer products are better because […]
Location, location, location. Does cannula site affect AID performance?
Rotate your injection or infusion sites. That’s a key message that anyone living with type 1 is delivered very early in their life with the […]
GLP1-RAs and Type 1 Diabetes: A retrospective study of incretin-based therapy use with Open Source AID.
So far in this series we’ve looked at why incretin therapy might be a useful adjunct to traditional type 1 treatment, and also how the […]
GLP1-RAs in Type 1 Diabetes: Dosing and Pharmacokinetics
As we discussed in the previous article, people are starting to use incretins as an adjunct therapy in the treatment of type 1 diabetes. All […]
GLP1-RAs in Type 1 Diabetes: more than meets the eye?
Some people will be aware, and some not, that there is a reasonable minority of people with Type 1 Diabetes using GLP-1 Receptor Agonists (GLP1-RAs) […]
Microtech’s Linx. An Aidex sequel.
In all the noise around EASD, you may not have noticed that Microtech have launched a new CGM. This is their follow up to Aidex, […]
Abbott’s Takedown Shakedown – an update
Following action from users, admins, healthcare staff and advocates, Abbott have responded on the takedown shenanigans. This seems to be a company statement that has […]